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Abstract
Purpose: To compare gross tumour volume (GTV) in oropharynx carcinomas using different intelligent imaging software 
and to evaluate which method is more reliable for tumour volume definition in comparison with 3D ProSoma software.
Material and methods: We retrospectively studied 32 patients with histopathologically confirmed oropharynx carcino-
mas on dual-source computed tomography (CT) (all patients underwent multislice CT examination after applying 
75 ml iodinated non-ionic contrast media). One radiologist calculated the tumour volume – manually measuring 
tumour length (L), width (W), and height (H) – and then calculated the tumour volume using the formula 0.5236 
× L × W × H. The other radiologist used the syngo.CT-Liver-Analysis software to calculate the tumour volumes. 
Both volume measuring methods were compared with the 3D ProSoma software, which is used by radiotherapists 
to calculate tumour volumes. Graphpad Prism software was used for statistical data.
Results: syngo.CT-Liver-Analysis software for gross tumour volume determination has greater reliability than the 
standard manual method with Syngo Plaza in comparison with the 3D ProSoma software.
Conclusions: syngo.CT-Liver-Analysis software is a reliable tool for GTV calculation, with a high correlation score, 
like that of radiotherapeutic 3D ProSoma software.
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Introduction
Oropharyngeal squamous cell carcinoma (OPSCC) has 
shown increasing incidence in recent decades due to an 
increase of human papillomavirus (HPV) distribution, 
especially among younger people. HPV-positive OPSCC 
cases now account for 70% of newly diagnosed OPSCCs 
in the United States of America [1]. Patients with a first 
diagnosis of oropharynx carcinoma often present with 
a locally advanced and surgically unresectable disease. 
But can tumour volume be an important pre-treatment 
parameter, like traditional TNM staging? Not only can the 
gross tumor volume (GTV) of oropharynx carcinomas be 
a pre-treatment parameter, but also three-dimensional 
images of OPSCC. In a clinical study [2] more accurate 
tumour volume estimation was shown to be an additional 
predictor between conventional radiotherapy (RT) alone, 
modern, highly conformal RT techniques, or more aggres-
sive, combined treatment. Despite the fact that the eighth 
version of American Joint Committee on Cancer – Union 
for International Cancer Control (AJCC – UICC) does 
not use the GTV, we think that radiologists should report 
tumour volume in their conclusions. The idea of correla-
tion between the GTV and the radiotherapy outcome is 
not new. The eighth edition reviewed staging system of 
oropharyngeal squamous cell carcinoma (TNM-System) 
from 2017 distinguishes between HPV-16-negative and 
HPV-16-positive tumours of the oropharynx. Today oro-
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pharyngeal cancers are treated with chemoradiation or 
first with surgery followed by radiation or chemoradia-
tion. However, in our institute the management of OPSCC 
is performed in a multidisciplinary tumour board setting. 
The choice of the right treatment can be complex. After an 
internal tumour board decision for radiation therapy, our 
patients are addressed to an external Institute of Radio-
therapy, where patients underwent intensity-modulated 
radiation therapy (IMRT) or volumetric modulated arc 
therapy (VMAT). GTV can predict local control at differ-
ent head and neck subsites, and local recurrence is higher 
in large-volume tumours than in low-volume lesions aris-
ing in the same anatomic subsite [3-7]. Tumour volume 
and tumour response to RT have a profound influence on 
the dose required to control a given type of tumour, as 
well as other factors: the large number of stem cells which 
must be sterilised, intrinsic radio sensitivity, repair, rate of 
repopulation/regeneration during therapy, reoxygenation, 
and redistribution. Tumour control can be influenced by 
other mechanisms such as biological heterogeneity as the 
number of clonogenic stem cells, tumour microenviron-
ment, or inter-cellular communication and genetic fac-
tors. An important factor influencing the RT outcome of 
patients with various types of tumours, including head 
and neck cancers, is that the clonogen number increases 
linearly with the tumour volume (TV) [8]. The TNM clas-
sification system for head and neck cancer incorporate 
only linear dimensions for a few tumour localisations. 
In the past, a two-dimensional approach in daily clinical 
practice or in measurement of TV or variations of TV are 
in use. Today, modern radiation oncology can precisely 
sculpt the radiation dose to target volumes while spar-
ing multiple critical normal tissues such as the brainstem, 
optic chiasm, optic nerves, and the spinal cord. 
Material and methods
Patients
Our internal institutional review board approved this study. 
Written informed consent was obtained from each patient. 
In this retrospective study we analysed 32 patients (74% 
men and 26% women) with histopathologically confirmed 
OPSCC between June 2018 and August 2019. Exclusion 
criteria were only poor-quality images (motion artefacts 
and from dental implants). All patients are listed in Table 1.
Data acquisition and scan protocol 
In our institute we used a dual-source CT scanner (So-
matom Drive; Siemens Healthcare, Forchheim, Germany) 
with the patient lying supine on the table with their arms 
along their body. All CT examinations were obtained after 
intravenous administration of 100 ml of 350 mg iodine/
ml iodinated contrast material (Iobitridol, Xenetix 350, 
Guerbet, France), at a flow rate of 2.5 ml/s, followed by 
a 50 ml saline flush, through an 18-gauge catheter placed 
in an antecubital vein using an automatic power injector 
(Medrad Stellant, Bayer). Scanning parameters are listed 
in Table 2.
Gross tumour volume calculation
One radiologist calculated the TV manually measuring tu-
mour length (L) and width (W) on the axial plane (Figure 1) 
and the height (H) on the sagittal plane (Figure 2). Then he 
calculated the TV using the formula 0.5236 × L × W × H (el-
lipsoid formula: volume = length × width × height × 0.5236) 
[9]. The other radiologist used syngo.CT-Liver-Analysis 
software to calculate the TV by contouring the volume 
only on axial CT images (Figure 3A). The advantage of 
this method is that a 3D model of the tumour is obtained 
(Figure 3B). Both volume-measuring methods were com-
pared with the results of GTV-contouring method using 
3D ProSoma software (MedCom, Darmstadt, Germany). 
In our radiotherapy department we use this software for 
organs at risk (OARs) contouring. We can build more 
treatment plans, and faster, and have more time to focus 
on delineation of GTVs and more time for our patients. 
The program allows the identification and contouring of the 
target volume and the creation of the clinical target volume 
(CTV). We also compared the times of the two methods: 
the first radiologist who used the simple formula needed 
on average one minute to determine the volume, while the 
second radiologist needed between three and five minutes 
with the syngo.via method, depending on the volume. 
The radiotherapist, on the other hand, needed between 1.5 
and 2 minutes per patient with the 3D ProSoma software. 
Statistical analysis
Graphpad Prism software was used for statistical data. 
To compare the two-volume calculating software packages 
we used the paired sample t-test. First, we compared the 
results from the ProSoma 3D software with the syngo.CT-
Liver-Analysis software (Figure 4) and obtained a p-value 
of 0.0254 (assuming that a p-value less than 0.05 is statis-
tically significant) and a correlation coefficient of 0.9980. 
The next step was a comparison between the results from 
the ProSoma 3D software with the Syngo Plaza software 
(Figure 5). In this case we obtained a p-value of 0.0001 
and a correlation coefficient of 0.9943. The interobserver 
variability was calculated using the Bland-Altman meth-
od, from which the standard deviation (SD) between 
Syngo Plaza software and ProSoma 3D software was 2.1 
and between syngo.CT-Liver-Analysis software and the 
ProSoma 3D software it was 1.34.
Results 
Our study suggests that syngo.CT-Liver-Analysis soft-
ware for GTV determination has a greater reliability than 
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standard manual method with Syngo Plaza in comparison 
with the 3D ProSoma software, as used by radiotherapists. 
Discussion
Traditionally syngo.CT-Liver-Analysis software is used for 
liver segmentation and for the identification of its vascular 
territories and subterritories, especially for liver surgery. 
Radiologists use this software to calculate and correct liver 
volumes, to compare resected and residual liver volume, 
for the segmentation of liver vessel tree structures, and 
Table 1. Volume data of the different software types and their corresponding histopathology
Patient Syngo Plaza CT 
volume





1 19.4 cm3 26.1 ml 24.8 ml Squamous carcinoma poorly differentiated HPV 16 pos
2 25.3 cm3 30.0 ml 28.2 ml Squamous carcinoma poorly differentiated HPV 16 pos
3 35.0 cm3 44.3 ml 40.3 ml Squamous carcinoma poorly differentiated HPV 16 neg
4 39.6 cm3 39.3 ml 39.0 ml Squamous carcinoma poorly differentiated HPV 16 pos
5 85.5 cm3 89.2 ml 86.0 ml Squamous carcinoma well differentiated HPV 16 neg
6 30.2 cm3 32.2 ml 32.0 ml Squamous carcinoma poorly differentiated HPV 16 neg
7 5.4 cm3 8.0 ml 9.0 ml Squamous carcinoma poorly differentiated HPV 16 pos
8 9.7 cm3 12.0 ml 11.7 ml Squamous carcinoma poorly differentiated HPV 16 pos
9 21.1 cm3 25.7 ml 23.7 ml Squamous carcinoma poorly differentiated HPV 16 neg
10 1.21 cm3 2.8 ml 1.8 ml Squamous carcinoma poorly differentiated HPV 16 neg
11 4.7 cm3 6.2 ml 5.0 ml Squamous carcinoma poorly differentiated HPV 16 pos
12 8.2 cm3 11.5 ml 10.0 ml Squamous carcinoma poorly differentiated HPV 16 pos
13 27.2 cm3 32.3 ml 30.0 ml Squamous carcinoma moderately differentiated HPV 16 neg
14 1.6 cm3 2.7 ml 3.0 ml Squamous carcinoma poorly differentiated HPV 16 neg
15 6.7 cm3 9.4 ml 7.0 ml Squamous carcinoma moderately differentiated HPV 16 pos
16 0.8 cm3 7.1 ml 10.0 ml Squamous carcinoma poorly differentiated HPV 16 neg
17 15.2 cm3 19.2 ml 18.5 ml Squamous carcinoma well differentiated HPV 16 pos
18 1.2 cm3 2.3 ml 2.0 ml Squamous carcinoma poorly differentiated HPV 16 neg
19 2.4 cm3 3.7 ml 2.5 ml Squamous carcinoma poorly differentiated HPV 16 neg
20 8.2 cm3 11.3 ml 12.0 ml Squamous carcinoma moderately differentiated HPV 16 pos
21 3.9 cm3 4.5 ml 5.0 ml Squamous carcinoma well differentiated HPV 16 neg
22 1.8 cm3 2.0 ml 2.0 ml Squamous carcinoma poorly differentiated HPV 16 neg
23 38.2 cm3 40.0 ml 40.5 ml Squamous carcinoma poorly differentiated HPV 16 neg
24 1.0 cm3 2.0 ml 2.5 ml Squamous carcinoma moderately differentiated HPV 16 neg
25 0.3 cm3 0.5 ml 0.6 ml Squamous carcinoma well differentiated HPV 16 pos
26 2.0 cm3 3.0 ml 2.7 ml Squamous carcinoma poorly differentiated HPV 16 neg
27 8.5 cm3 11.0 ml 12.0 ml Squamous carcinoma poorly differentiated HPV 16 neg
28 10.5 cm3 12.0 ml 12.3 ml Squamous carcinoma well differentiated HPV 16 neg
29 7.8 cm3 10.3 ml 9.5 ml Squamous carcinoma poorly differentiated HPV 16 neg
30 1.0 cm3 2.0 ml 2.1 ml Squamous carcinoma well differentiated HPV 16 pos
31 2.5 cm3 4.0 ml 3.6 ml Squamous carcinoma moderately differentiated HPV 16 neg
32 4.0 cm3 5.2 ml 4.6 ml Ssquamous carcinoma well differentiated HPV 16 neg
Table 2. Scanning parameters
Parameter Somatom definition drive 
Scanning technique Spiral
Scan direction Caudocranial
Care kV 80  
Rotation time 1 s  
Pitch 0.8
to visualise tumour position in relation to vessels. Our 
goal was to find a new field of activity for this software. 
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Figure 4. Comparison between 3D ProSoma software and syngo.CT-Liver- 
Analysis software
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3D ProSoma software volume
syngo.CT-Liver-Analysis volume
Syngo Plaza CT volume
3D ProSoma software volume
Figure 1. Manual measurement of length and width Figure 2. Manual measurement of thickness
Figure 3. Second method of tumour volume analysing with syngo.CT-Liver- 
Analysis software (A = anterior). The red line represents the delimitation 
line of a squamous cell carcinoma of the posterior base of tongue (white 
arrow). [11] means the 11th slice
A B
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Figure 6. Examples of treatment planning software (ProSoma 3D) for oropharynx carcinomas with VMAT: 6 arcs are implemented in order to avoid shoulders 
(from arc angle 186° to 235°, 270° to 90°, 125° to 174°, clockwise and anticlockwise), help structures as spine expanded of 5 cm subtracted with PTV low-
dose expanded of 0.6 cm was defined to minimise low-dose distribution outside PTV and around the spine
A B
Radiotherapists and radiologists should communicate 
more with each other, especially because radiologists often 
have little knowledge about radiotherapeutic procedures. 
Limitations of this study are the small patient numbers 
and the use of only one radiological software package. 
In terms of time, we have seen that the method with the 
syngo.CT-Liver-Analysis software takes longer. The fast-
est method remains the simplest at present, although it 
must be said that the sensitivity decreases in comparison. 
Radia tion therapy for head and neck cancer has evolved 
and has moved from 3-D conformal radiotherapy (3D-
CRT) to intensity-modulated radiotherapy (IMRT). The 
main disadvantages of IMRT are the time-consuming 
treatment planning process and the larger number of 
multiple fixed-angle beams and monitor units (MUs), 
which increases the treatment delivery time. Volumetric 
modulated arc radiotherapy (VMAT) is a new radiation 
therapy technique in which treatment is delivered using 
a continuous arc motion of the gantry with simultane-
ous variation of the multi-leaf collimator (MLC) position, 
gantry speed, and dose rate with the ability to produce 
highly conformal plans in a short delivery time. In our 
institution oropharynx tumours are treated with sequen-
tial VMAT or VMAT-simultaneous integrated boost (SIB-
VMAT) with Raystation software (Figure 6A and 6B). 
There are many fractionation schedules across institutions, 
but the most commonly prescribed doses are biologically 
equivalent to 70 Gy to gross disease and 60/54 Gy to sus-
picious nodes. At our institution we preferer a simultaneous 
integrated boost (SIB) with VMAT technique in which dif-
ferent dose levels are assigned to the various target volumes 
– dose 66/2.2 Gy to the GTV and a margin of protentional 
micro scopic spread and positive neck nodes and 54/1.8 Gy 
to the clinically negative nodal regions. Thermoplastic masks 
are used to keep the patient in the exact position (Figure 7). 
The dose and fractionation may also be influenced by in-
clusion or exclusion of concurrent chemotherapy. Gross 
target volume (GTV-T) is defined by the radio-oncologist 
as the extent of the primary tumour, shown by imaging 
studies and physical examination, with margin of 5 mm 
around the obtained clinical target volume (CTV-T). 
Gross nodal disease is defined as focal nodal necrosis or 
heterogeneity, or as short-axial diameter > 10 mm (GTV-N) 
plus a margin of 10 mm for potential direct routes of mi-
croscopic spread (CTV-N) as reported in the DAHANCA 
guidelines [10]. Hence, the GTV and CTV are included in 
planning target volume (PTV) to account for patient setup 
errors. The CTV does not overlap uninvolved critical ad-
jacent structures such the optic nerves or chiasm, even 
if the physician planned to minimise the dose to these 
structures. This is an issue for potential interobserver and 
intraobserver variability. Some problems in the tumour 
boundary definition on CT derives from the difficulty to 
separate the tumour from the peritumoral oedema area, 
which is excluded from the region of interest (ROI). For 
this reason, magnetic resonance imaging (MRI) is often 
used, which is more sensitive than CT in distinguishing 
tumours from normal adjacent structures. The use of MRI 
can reduce inter-observer variability [11]. Also, fluorine 
18 fluorodeoxyglucose (18F-FDG) positron emission to-
mography (PET) provides not only anatomy but also non-
invasive functional imaging and biological metabolism. 
FDG-PET is effective for defining GTV in radiotherapy 
planning for squamous cell carcinoma of the head and 
Figure 7. Thermoplastic mask to keep patient in the exact position
Sigmund Stuppner, Justyna Waskiewicz, Antonio Ruiu  
e292 © Pol J Radiol 2020; 85: e287-e292
neck [12]. Tumour volume in HNC is often more strongly 
associated with local control than tumour stage. Variation 
in TV or GTV contouring are the greatest geometrical 
uncertainties in the entire treatment care process, and in-
adequate delineation can compromise the curative intent. 
In this context multidisciplinary collaboration between 
surgeons, radiologists, and radiation oncologists is man-
datory to achieve improved tumour control via better TV 
definition.
Conclusions
Syngo.ct-Liver-Analysis software is, in our opinion, an 
important tool for GTV calculation, with a high correla-
tion score and good standard deviation (SD), like that of 
radiotherapeutic 3D ProSoma software. 
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